Study Using the CervicalStim Device Following Cervical Fusion

Overview

This study examines the effect of adjunctive use of the CervicalStim bone growth stimulator on cervical fusion rate in high risk subjects who have undergone cervical fusion surgery. All participants will wear the bone growth stimulator every day for 4 hours/day for 6 months.

Full Title of Study: “A Multi-Center, Open-Label, Prospective Study of CervicalStim Device™ as Adjunctive Care Following Cervical Fusion”

Study Type

• Study Type: Observational [Patient Registry]
• Study Design
  • Time Perspective: Prospective
• Study Primary Completion Date: August 3, 2021

Detailed Description

The purpose of this post market prospective study is to examine the effect of the adjunctive use of the Orthofix CervicalStim device on cervical fusion rate in high risk subjects who have undergone cervical fusion surgery. High risk subjects are those who are having a multi-level (2 or more) cervical fusion, who are smokers, who are diabetic or those who are osteoporotic. Because this is a post market prospective study, subjects who are enrolled in this study will be identified by the Investigator as needing cervical fusion surgery and asked to participate in a study looking at the efficacy of cervical fusion with adjunctive use of the CervicalStim bone growth simulator. The type of cervical fusion surgery performed is up to the Investigator; the subjects in the study must be agreeable to using the bone growth stimulator for 6 months post-surgery. The subjects will be followed for 12 months.

Interventions

• Device: CervicalStim bone growth stimulator
  • Orthofix CervicalStim bone growth stimulator

Arms, Groups and Cohorts

• CervicalStim PEMF group
  • all subjects will receive active CervicalStim bone growth stimulator

Clinical Trial Outcome Measures

Primary Measures

• cervical fusion rate
  • Time Frame: 12 months
  • fusion rate assessed via radiographic confirmation (Xray and CT)

Secondary Measures

• Device Compliance
  • Time Frame: 6 months
  • actual minutes per day device was used compared with prescribed use
• revision rate
  • Time Frame: 12 months
  • how many subjects had to be revised at the same level(s) during the course of the study
• SF-36
  • Time Frame: 12 months
  • used to assess the effect of PEMF therapy on the subject’s quality of life
• Neck Disability Index (NDI)
  • Time Frame: 12 months
  • used to assess the effect of PEMF therapy on the reduction of neck pain
• EQ-5D
  • Time Frame: 12 months
  • used to assess the effect of PEMF therapy on quality of life as well as economic impact
• VAS pain
  • Time Frame: 12 months
  • used to assess the effect of PEMF therapy on reduction of pain

Participating in This Clinical Trial

Inclusion Criteria

1. Male or female, ≥ 18 years of age at the time of Informed Consent. 2. Requires a cervical fusion surgery within 30 days of Informed Consent signing. a. Surgical approach is at the physician's discretion. 3. Subject has one or more high risk factors: 1. Is currently using nicotine 2. multi-level cervical fusion surgery planned 3. Prior failed fusion at any cervical level 4. Subject reported diabetes 5. Subject reported osteoporosis 4. Body mass index ≤ 45 kg/m2 at the time of consent. 5. Must have reliable access to an iPhone or an iPad with Wi-Fi access for downloading the free device-specific app (iPhone 5S or higher, iPad, iPad Pro, iPad mini or iTouch using iOS v.9.3 or later). a. When the android version of the mobile app for the CervicalStim device becomes available (estimated to be Dec. 2017), subjects who have reliable access to devices using android operating systems will be eligible for study inclusion. 6. Able and willing to complete electronic questionnaires and able to read and understand study instructions in English. 7. Able and willing to comply with the study plan and able to understand and sign the study-specific Informed Consent Form (ICF). Exclusion Criteria:

1. Current alcoholism and/or any known current addiction to pain medications. 2. Any active malignancy or prior history of malignancy within last 5 years prior to fusion (except basal cell carcinoma of the skin). 3. Any clinically significant finding that places the subject at health risk, impacts the study, or affects completion of the study, in the opinion of the Investigator. 4. Any psychiatric illness that prevents subject from completing the assessments accurately, in the opinion of the Investigator. 5. Subject is a prisoner.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

• Lead Sponsor
  • Orthofix Inc.
• Provider of Information About this Clinical Study
  • Sponsor
• Overall Official(s)
  • James T Ryaby, PhD, Principal Investigator, Orthofix Inc.